This paper is marked retracted in the scholarly record (OpenAlex). Interpret its findings with caution.
Retraction Note: The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma
Zhongqiang Zhang, Xiao Tan, Jing Luo, Hongliang Yao, Zhongzhou Si, Jing-Shan Tong

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRNA modifications and cancer · Protein Degradation and Inhibitors · Epigenetics and DNA Methylation
Retraction Note to: Cell Death and Disease 10.1038/s41419-020-03123-3, published online 23 October 2020
The Editor-in-Chief has retracted this article. An investigation by the National Natural Science Foundation of China Supervision Committee confirmed multiple overlaps in figures between different publications and found these images came from a third party provider. Specifically, two panels from Fig. 2H were found to overlap with three panels from Fig. 5D from another article by different authors [1], Fig. 4D from [2], and Fig. 2K from [3]. Figure 7D was found to overlap with Fig. 6D from [4]. All articles were under consideration at the same time. The Editor has lost confidence in the data and conclusions of this article.
The authors have not responded to correspondence from the publisher regarding this retraction.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Han S, Zhen W, Guo T, Zou J, Li F. SETDB 1 promotes glioblastoma growth via CSF-1-dependent macrophage recruitment by activating the AKT/m TOR signaling pathway. J Exp Clin Cancer Res. 2020;39:218. 10.1186/s 13046-020-01730-8. Retraction in: J Exp Clin Cancer Res. 2022;41:280. 10.1186/s 13046-022-02495-y.10.1186/s 13046-020-01730-8PMC 756033933059737 · doi ↗ · pubmed ↗
- 2Wang Z, Zhao Y, Xu H, Liang F, Zou Q, Wang C, Jiang J, Lin F. Ct BP 1 promotes tumour-associated macrophage infiltration and progression in non-small-cell lung cancer. J Cell Mol Med. 2020;24:11445–56. 10.1111/jcmm.15751. Erratum in: J Cell Mol Med. 2024;28:e 18189. 10.1111/jcmm.18189.10.1111/jcmm.15751 PMC 757628032910558 · doi ↗ · pubmed ↗
